RESOLVE-IT Failure Dashes Genfit's NASH Hopes

Elafibranor Missed Trial Endpoints At The Interim Stage

 
• By Sten Stovall
  
Target
RESOLVE-IT missed its primary endpoint for treating NASH • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D